Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;4(4):116-21.

Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy

Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy

Brian M Alexander et al. Gastrointest Cancer Res. 2011 Jul.

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) arising in intraductal papillary mucinous neoplasms (IPMN) may represent a different biologic entity than classic PDAC, and there is little evidence to inform adjuvant treatment decisions. The purpose of this study was to identify prognostic factors for PDAC arising in IPMN and determine the benefit of postoperative adjuvant therapy.

Methods: Forty-four patients without previous therapy who underwent surgery for invasive PDAC arising in association with IPMN at our institution were identified. Medical records were reviewed for clinical and pathologic features, adjuvant therapy, and outcomes.

Results: On univariate analysis, positive nodes (hazard rate [HR] 14, 95% confidence interval [CI] 4.2-44), CA 19-9 > 80 (HR 6.2, 95% CI 2.2-17), lymphovascular invasion (HR 4.7, 95% CI 1.5-15), perineural invasion (HR 3.9, 95% CI 1.5-10), and positive margins (HR 3.1, 95% CI 1.2-8.0) were associated with inferior cancer-specific survival. Patients with positive nodes who received adjuvant therapy had higher median cancer-specific survival (20 months) than those who received no adjuvant therapy (3.3 months).

Conclusions: Patients with PDAC arising in IPMN presented at an earlier stage than is reported for classical PDAC. Adjuvant chemoradiotherapy was associated with improved overall and cancer-specific survival for patients with advanced disease. These hypothesis-generating results require validation in a larger prospective trial.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overall survival of patients segregated by nodal status (upper left), elevated CA 19-9 (upper right), lymphovascular invasion (bottom left), and perineural invasion (bottom right). LVI = lymphovascular invasion; PNI = perineural invasion.
Figure 2.
Figure 2.
Cancer-specific survival of patients segregated by nodal status (upper left), elevated CA 19-9 (upper right), lymphovascular invasion (bottom left), and perineural invasion (bottom right). LVI = lymphovascular invasion; PNI = perineural invasion.

References

    1. Conlon KC: Intraductal papillary mucinous tumors of the pancreas. J Clin Oncol 23:4518–4523, 2005 - PubMed
    1. Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, et al. : Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol 157:755–761, 2000 - PMC - PubMed
    1. Moore PS, Orlandini S, Zamboni G, et al. : Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 84:253–262, 2001 - PMC - PubMed
    1. Sohn TA, Yeo CJ, Cameron JL, et al. : Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 239:788–797, 2004; discussion 97–99 - PMC - PubMed
    1. Terris B, Blaveri E, Crnogorac-Jurcevic T, et al. : Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol 160:1745–1754, 2002 - PMC - PubMed

LinkOut - more resources